Preethi Sundaram Sells 2,324 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Preethi Sundaram sold 2,324 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the sale, the insider now owns 42,681 shares in the company, valued at approximately $1,127,205.21. This trade represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Preethi Sundaram also recently made the following trade(s):

• On Wednesday, June 11th, Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $26.42, for a total value of $42,272.00.

Catalyst Pharmaceuticals Trading Down 2.3%

Shares of CPRX traded down $0.56 during mid-day trading on Friday, hitting $23.73. The company's stock had a trading volume of 522,421 shares, compared to its average volume of 1,124,600. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of 20.12, a PEG ratio of 3.31 and a beta of 0.72. The company's 50-day moving average is $23.81 and its 200-day moving average is $22.85. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.75 and a 52-week high of $26.58.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC lifted its stake in shares of Catalyst Pharmaceuticals by 1.0% during the first quarter. Algert Global LLC now owns 48,390 shares of the biopharmaceutical company's stock worth $1,173,000 after buying an additional 470 shares during the period. Hancock Whitney Corp boosted its stake in shares of Catalyst Pharmaceuticals by 1.4% during the 1st quarter. Hancock Whitney Corp now owns 38,847 shares of the biopharmaceutical company's stock worth $942,000 after acquiring an additional 525 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Catalyst Pharmaceuticals by 5.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 580 shares in the last quarter. Finally, Hohimer Wealth Management LLC raised its holdings in Catalyst Pharmaceuticals by 3.6% in the 1st quarter. Hohimer Wealth Management LLC now owns 18,070 shares of the biopharmaceutical company's stock worth $438,000 after purchasing an additional 629 shares during the period. Hedge funds and other institutional investors own 79.22% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on CPRX. Stephens reaffirmed an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Robert W. Baird boosted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Six equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.83.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.